BioMarin Pharmaceutical | BMRN - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Alnylam Pharmaceuticals USD 5.56B 429.22M 2026-06
Amgen USD 95.64B 3.14B 2026-06
Bayer EUR 107.29B 659M 2026-06
Biogen USD 32.09B 2.6B 2026-06
BioMarin Pharmaceutical USD 11.72B 3.13B 2026-06
Gilead Sciences USD 49.36B 6.92B 2026-06
Incyte USD 7.87B 533.53M 2026-06
Insmed USD 2.1B 26.7M 2026-06
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
Moderna USD 10.96B 527M 2026-06
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 41.73B 861.8M 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 128.02B 1.22B 2026-03
Sarepta Therapeutics USD 3.19B 9.58M 2026-06
Ultragenyx Pharmaceutical USD 1.26B 32M 2026-06
United Therapeutics USD 7.22B 505.9M 2026-06
Vertex Pharmaceuticals USD 27.42B 938.9M 2026-06